In this CME activity, Susana M. Campos, MD, MS, MPH, reviews some of the recent clinical developments in the treatment of patients with advanced ovarian cancer with PARP inhibitors. We welcome you to learn more about the updated data from key clinical studies of PARP inhibitor maintenance therapy in advanced ovarian cancer, and the implications of the results on the current and emerging concepts in ovarian cancer clinical practice.
0.5 AMA PRA Category 1 CreditsTM
This activity is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals involved in the treatment of patients with advanced ovarian cancer.
This educational activity is supported by an educational grant from GlaxoSmithKline.